Search

Viking Therapeutics Inc

Закрыт

СекторЗдравоохранение

24.79 2.31

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

24

Макс.

24.86

Ключевые показатели

By Trading Economics

Доход

30M

-128M

Прибыль на акцию

-1.1

Сотрудники

65

EBITDA

30M

-128M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+275.84% upside

Дивиденды

By Acuity

Следующий отчет о доходах

28 окт. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-863M

3.2B

Предыдущая цена открытия

22.48

Предыдущая цена закрытия

24.79

Viking Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 окт. 2026 г., 20:02 UTC

Social Media

Shares of Viking Therapeutics Inc fell sharply as the company prepares to report earnings on October 28th, breaking a recent trend of higher daily closes.

22 окт. 2026 г., 20:07 UTC

News
Correlated Moves
Macro Event

Viking Therapeutics sees increased bearish sentiment with 6.55k puts traded, 1.6 times expected volume, ahead of its Q3 results on October 28, 2026.

21 окт. 2026 г., 23:06 UTC

News

Viking Therapeutics Inc will report its third-quarter financial results on October 28, 2026, and host a conference call at 4:30 p.m. ET.

20 окт. 2026 г., 23:06 UTC

News

Viking Therapeutics Inc is trading higher in after-market hours.

19 окт. 2026 г., 23:41 UTC

Viking Therapeutics Inc shares are modestly higher in after-market trading, reaching their highest point since Monday's close after bouncing back from earlier lows.

16 окт. 2026 г., 20:02 UTC

Social Media
Correlated Moves

Shares of Viking Therapeutics Inc are declining amid a broader downturn in the biotechnology sector, with the SPDR S&P Biotech ETF also lower.

15 окт. 2026 г., 20:04 UTC

News
Social Media

Viking Therapeutics shares advanced after Oppenheimer maintained an "outperform" rating with a $120 price target and UBS initiated coverage with a $94 price target.

14 окт. 2026 г., 23:02 UTC

News
Social Media

Viking Therapeutics shares advanced in after-market trading after UBS initiated coverage with a Buy rating and a price target of $94.00.

13 окт. 2026 г., 19:51 UTC

Viking Therapeutics Inc shares fell sharply, reaching their lowest point of the day and remaining well below their 20-day moving average.

9 окт. 2026 г., 20:07 UTC

Correlated Moves
News
Social Media

Viking Therapeutics is seeing increased interest amid reports of a potential bidding war, with speculation about suitors including LLY and positive momentum in the biotech sector.

8 окт. 2026 г., 20:07 UTC

Social Media

Shares of Viking Therapeutics Inc declined notably during the session, continuing a downward trend since Wednesday's close, reaching a low before a slight recovery.

7 окт. 2026 г., 20:08 UTC

News
Event
Social Media

Viking Therapeutics Inc shares are trading higher as Truist Securities lowers its price target to $85.00 while maintaining a Buy rating.

6 окт. 2026 г., 23:01 UTC

Event

Viking Therapeutics Inc has initiated an exploratory oral maintenance dosing study of VK2735, with the stock advancing in after-market trading following the announcement.

5 окт. 2026 г., 20:06 UTC

Social Media
News

Viking Therapeutics Inc shares fell sharply, reflecting a significant decline from a recent high of $43.10, closing down notably since Friday.

2 окт. 2026 г., 20:07 UTC

Viking Therapeutics Inc shares fell sharply, continuing a decline since Thursday's close and closing significantly below the 20-day moving average.

1 окт. 2026 г., 23:01 UTC

Social Media

Viking Therapeutics Inc. is seeing increased social media attention, with its stock rising in after-market trading to $30.51 amid acquisition speculation.

30 сент. 2026 г., 20:07 UTC

Social Media

Viking Therapeutics shares are advancing today as discussions on VK2735's weight loss data gain traction, with Cantor setting a $100 price target.

29 сент. 2026 г., 23:05 UTC

Viking Therapeutics Inc is seeing a modest increase in after-market trading, recovering from an initial low before settling back slightly.

28 сент. 2026 г., 20:03 UTC

News
Social Media

Viking Therapeutics Inc shares fell sharply amid online posts about its VK2735 drug, raising concerns of panic selling despite promising trial results.

25 сент. 2026 г., 20:02 UTC

Social Media

Viking Therapeutics shares are lower amid volatility, despite positive trial data, as concerns over a recent capital raise and share sales at $35 persist.

24 сент. 2026 г., 20:03 UTC

News
Social Media

Viking Therapeutics Inc. shares fell sharply after announcing a $500 million capital raise, including 7.86 million shares priced at $35.00 each, amid dilution concerns.

23 сент. 2026 г., 23:01 UTC

News
Social Media

Viking Therapeutics plans to raise $400 million through stock and convertible notes offerings, causing significant after-hours trading decline amid dilution concerns.

22 сент. 2026 г., 23:01 UTC

News
Social Media

Viking Therapeutics Inc gained after Oppenheimer raised its price target for VK2735 from $100 to $120, citing strong trial results and increased retail sentiment.

21 сент. 2026 г., 23:01 UTC

Social Media

Viking Therapeutics Inc is advancing in after-market trading following notable social media interest, breaking a streak of ten consecutive lower daily closes.

18 сент. 2026 г., 20:07 UTC

Viking Therapeutics Inc is declining, continuing a downward trend as the broader market marks its tenth consecutive session of losses.

17 сент. 2026 г., 19:16 UTC

Social Media

Viking Therapeutics Inc is trading higher as social media buzz surrounds VK2735 ahead of its anticipated Phase 3 trials, despite recent declines.

16 сент. 2026 г., 23:06 UTC

Viking Therapeutics Inc is trading modestly higher in after-market hours, following eight consecutive lower daily closes and recent broader market declines.

15 сент. 2026 г., 23:02 UTC

Viking Therapeutics Inc shares are higher during after-market hours, reflecting broader market trends despite recent economic indicators suggesting a slowdown in manufacturing.

14 сент. 2026 г., 19:36 UTC

Viking Therapeutics Inc shares are lower, continuing a trend of declines amid broader market weakness and rising crude oil prices affecting sentiment.

11 сент. 2026 г., 23:06 UTC

Viking Therapeutics Inc. shares are higher in after-market trading, despite routine fluctuations, and remain below their 20-day moving average.

Сравнение c конкурентами

Изменение цены

Viking Therapeutics Inc Прогноз

Целевая цена

By TipRanks

275.84% рост

Прогноз на 12 месяцев

Средняя 91.706 USD  275.84%

Максимум 125 USD

Минимум 38 USD

Основано на мнении 18 аналитиков Wall Street, спрогнозировавших целевые цены для Viking Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

18 ratings

17

Покупка

1

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
help-icon Live chat